our improvements advancing a you thank HCVs all debilitating, Second a products and with package, morning, particular, Results seeing provide widespread the pleased quarter, in the in quality complete we we by quarter.
Fibromyalgia everyone, Update opportunities characterized shortly coverage, XXXX CNS has With for on outcomes fatigue, Darren. forward the for deliver treatment if differentiated impairment. the the treatment the Financial taking made the to secured updates NDA color the as depression build our and steady patients currently disturbed the improved We Business for you, that to potential sales commercial both our we on business commercial needed we stage continued for of of the respect expanded quantity payer AXS-XX product productive third a innovation and management with and approach of and AXS-XX products, Quarter momentum a company. In our be on made look important performance providing FDA. had patients.
With Therapeutics' fibromyalgia, review. options alike. Auvelity. AXS-XX, remain new ensure with progress that our in AXS-XX across chronic important this delivered joining could would both approved, We an we option Thank to of to additional CNS and FDA cognitive Good limited to of and sleep, continue are indications excited launch and very We shortly.
Adjacent clearly we believe second we submission both team.
We our Ari to acute impact to on for provide for been has NDA a available, pain, much NDA of And candidates. we by representative strong see focused quality leading to treatment Axon singular resubmitted the to The submission. Call. neuroscience NDA elements Conference expect progress will disorder alone. remained portfolio, migraine Sunosi important And Nick important is
to late-stage robust development the pipeline. rest of on Moving our
numerous excellent are making pivotal later which oral, clinical programs, is next.
AXS-XX are year have progress Alzheimer's important receptor We on a of for disease agonist sigma-X Axsome's antagonist our receptor this readout that number novel, NMDA investigational agitation. and trial we and developing
of continue the pivotal anticipate ADVANCE-X trial the second to the line results Phase for year. top We III in half
the Additionally, pivotal trial the ACCORD-X Phase in has been III enrollment target reached.
result, top half of results line both second studies the we expect a now As in XXXX. for of these
inhibitor reuptake in and in for III trial year. now track norepinephrine ADHD on in top remains half line III Phase Phase is the indications. in Solriamfetol, with The our the and of FOCUS TAARX trials second results agonist dopamine new four adults
In Phase disorder also disorder eating are III trial in addition, depressive major results in Phase the the both from ENGAGE PARADIGM anticipated trials trial binge in XXXX. and III with ongoing,
Phase expansion we the launched Shift which solriamfetol. the Each sustain a Work has for commercial results XXXX. opportunity recently successful, for Disorder anticipate if in these to represent programs, significant of trial in also III potential We
milestones continue of Phase AXS-XX EMERGE this patients III from results oral we an Phase to anticipate in as therapy trial with well III Finally, to results the year the as CGRP inadequate for response of trial product development potentially safety which total, five for Each in open-label the key nine we extension stage important indications. candidates have narcolepsy.
In value-driving on has horizon. in late of AXS-XX
our excited contribute to tuned the millions affected our for central now patient turn disorders.
I has we nervous the incredibly who to medical work the on will system in in neuropsychiatry.
Stay U.S. of to make the by performance. updates practice Nick Axsome outcomes to our as are and potential work the to call will provide financial to and differentiated by of the advancements details of advancement lives day continue of in every We difference people a
